Sr. Fellow / Sr.Director Genentech Inc South San Francisco, California
The future of clinical trials will be meeting patients where they are. Decentralization broadens trial access to reach a larger number & a more diverse pool of patients, which will be increasingly critical to patient enrollment and retention. Patient centric technologies such as home sampling can enable decentralized clinical trials. These technologies can decrease patient burden, enabling less painful blood sampling and convenient collection options to the clinic. In addition, implementation of these technologies can significantly increase clinical trial accessibility and speed by expanding our geographic reach and participation of diverse patient populations. The objective of this study was to compare the clinical pharmacokinetics of a diverse set of large and small molecules, from samples generated using conventional venipuncture versus two capillary microsampling devices collecting either liquid blood (Tasso+) or dry blood (Neoteryx Mitra). This talk will present our results as well as the challenges and opportunities in implementation of these technologies.
Learning Objectives:
Introduction to patient centric technologies
The advantages of decentralized clinical trials and impact on drug development
Challenges and considerations with microsampling technologies using small and large molecules.